A 3 Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy

• Published in: Medicinal research reviews 2018-07, Vol.38 (4), p.1031-1072
• Main Authors: Jacobson, Kenneth A, Merighi, Stefania, Varani, Katia, Borea, Pier Andrea, Baraldi, Stefania, Aghazadeh Tabrizi, Mojgan, Romagnoli, Romeo, Baraldi, Pier Giovanni, Ciancetta, Antonella, Tosh, Dilip K, Gao, Zhan-Guo, Gessi, Stefania
• Format: Article
• Language: English
• Subjects: Adenosine A3 Receptor Agonists - pharmacology; Allosteric Site; Animals; Arthritis, Rheumatoid - drug therapy; Carcinoma, Hepatocellular - drug therapy; Clinical Trials as Topic; Crystallography, X-Ray; Humans; Immune System; Inflammation - drug therapy; Liver Neoplasms - drug therapy; Mice; Molecular Dynamics Simulation; Psoriasis - drug therapy; Rats; Receptor, Adenosine A3 - metabolism; Structure-Activity Relationship
• ISSN: 0198-6325; 1098-1128
• DOI: 10.1002/med.21456

The A adenosine receptor (A AR) subtype is a novel, promising therapeutic target for inflammatory diseases, such as rheumatoid arthritis (RA) and psoriasis, as well as liver cancer. A AR is coupled to inhibition of adenylyl cyclase and regulation of mitogen-activated protein kinase (MAPK) pathways, leading to modulation of transcription. Furthermore, A AR affects functions of almost all immune cells and the proliferation of cancer cells. Numerous A AR agonists, partial agonists, antagonists, and allosteric modulators have been reported, and their structure-activity relationships (SARs) have been studied culminating in the development of potent and selective molecules with drug-like characteristics. The efficacy of nucleoside agonists may be suppressed to produce antagonists, by structural modification of the ribose moiety. Diverse classes of heterocycles have been discovered as selective A AR blockers, although with large species differences. Thus, as a result of intense basic research efforts, the outlook for development of A AR modulators for human therapeutics is encouraging. Two prototypical selective agonists, N6-(3-Iodobenzyl)adenosine-5'-N-methyluronamide (IB-MECA; CF101) and 2-chloro-N6-(3-iodobenzyl)-adenosine-5'-N-methyluronamide (Cl-IB-MECA; CF102), have progressed to advanced clinical trials. They were found safe and well tolerated in all preclinical and human clinical studies and showed promising results, particularly in psoriasis and RA, where the A AR is both a promising therapeutic target and a biologically predictive marker, suggesting a personalized medicine approach. Targeting the A AR may pave the way for safe and efficacious treatments for patient populations affected by inflammatory diseases, cancer, and other conditions.